

Todd M Kolb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7431918/publications.pdf>

Version: 2024-02-01

52
papers

1,349
citations

361413

20
h-index

361022

35
g-index

55
all docs

55
docs citations

55
times ranked

1897
citing authors

#	ARTICLE	IF	CITATIONS
1	How We Would Treat Our Own Pulmonary Hypertension if We Needed to Undergo Cardiac Surgery. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 1540-1548.	1.3	5
2	Left Atrial Ablation for the Management of Atrial Tachyarrhythmias in Patients with Pulmonary Hypertension: A Case Series. <i>HeartRhythm Case Reports</i> , 2022, 8, 275-279.	0.4	1
3	Association of soluble Flt-1 with heart failure and cardiac morphology: The MESA angiogenesis study. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 619-625.	0.6	4
4	Causes and outcomes of ICU hospitalisations in patients with pulmonary arterial hypertension. <i>ERJ Open Research</i> , 2022, 8, 00002-2022.	2.6	8
5	Right Atrial Pacing to Improve Acute Hemodynamics in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 508-511.	5.6	4
6	Kussmaul's Sign in Pulmonary Hypertension Corresponds With Severe Pulmonary Vascular Pathology Rather Than Right Ventricular Diastolic Dysfunction. <i>Circulation: Heart Failure</i> , 2021, 14, e007461.	3.9	6
7	A novel approach to perioperative risk assessment for patients with pulmonary hypertension. <i>ERJ Open Research</i> , 2021, 7, 00257-2021.	2.6	6
8	Exercise right ventricular ejection fraction predicts right ventricular contractile reserve. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 504-512.	0.6	15
9	Associations of Angiopoietins With Heart Failure Incidence and Severity. <i>Journal of Cardiac Failure</i> , 2021, 27, 786-795.	1.7	12
10	Anesthetic techniques for patients with pulmonary hypertension undergoing ophthalmologic procedures: A case series. <i>Journal of Clinical Anesthesia</i> , 2021, 71, 110220.	1.6	2
11	PDE9A deficiency does not prevent chronic hypoxic pulmonary hypertension in mice. <i>Physiological Reports</i> , 2021, 9, e15057.	1.7	2
12	Right ventricular function as assessed by cardiac magnetic resonance imaging-derived strain parameters compared to high-fidelity micromanometer catheter measurements. <i>Pulmonary Circulation</i> , 2021, 11, 1-10.	1.7	4
13	Insulin-like growth factor binding protein-2: a new circulating indicator of pulmonary arterial hypertension severity and survival. <i>BMC Medicine</i> , 2020, 18, 268.	5.5	15
14	Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , 2019, 9, 1-9.	1.7	32
15	SU5416 does not attenuate early RV angiogenesis in the murine chronic hypoxia PH model. <i>Respiratory Research</i> , 2019, 20, 123.	3.6	6
16	Validation of the <sc>REVEAL</sc> Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. <i>Arthritis and Rheumatology</i> , 2019, 71, 1691-1700.	5.6	15
17	A nonapoptotic endothelial barrier-protective role for caspase-3. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2019, 316, L1118-L1126.	2.9	24
18	Disconnect between Fibrotic Response and Right Ventricular Dysfunction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1550-1560.	5.6	34

#	ARTICLE	IF	CITATIONS
19	Pulmonary arterial hypertension and atrial arrhythmias: incidence, risk factors, and clinical impact. <i>Pulmonary Circulation</i> , 2018, 8, 1-8.	1.7	43
20	Pulmonary Effective Arterial Elastance as a Measure of Right Ventricular Afterload and Its Prognostic Value in Pulmonary Hypertension Due to Left Heart Disease. <i>Circulation: Heart Failure</i> , 2018, 11, e004436.	3.9	85
21	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 166-174.	5.6	17
22	Right Ventricular Myofilament Functional Differences in Humans With Systemic Sclerosis-Associated Versus Idiopathic Pulmonary Arterial Hypertension. <i>Circulation</i> , 2018, 137, 2360-2370.	1.6	102
23	The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study. <i>Pulmonary Circulation</i> , 2018, 8, 1-11.	1.7	30
24	Risk assessment in scleroderma patients with newly diagnosed pulmonary arterial hypertension: application of the ESC/ERS risk prediction model. <i>European Respiratory Journal</i> , 2018, 52, 1800497.	6.7	32
25	Reply: Can treprostinil-induced early gastrointestinal side effects serve as predictors of pulmonary arterial hypertension prognosis?. <i>International Journal of Cardiology</i> , 2018, 264, 188.	1.7	0
26	Supply and Demand: Micro(vascular) Economics of the Right Ventricle in Pulmonary Hypertension. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 59, 410-411.	2.9	2
27	Focused Review of Perioperative Care of Patients with Pulmonary Hypertension and Proposal of a Perioperative Pathway. <i>Cureus</i> , 2018, 10, e2072.	0.5	20
28	Poor survival in patients with scleroderma and pulmonary hypertension due to heart failure with preserved ejection fraction. <i>Pulmonary Circulation</i> , 2017, 7, 409-420.	1.7	31
29	What are the side effects? The association between pulmonary vasodilator adverse drug events and clinical outcomes in patients with pulmonary arterial hypertension. <i>International Journal of Cardiology</i> , 2017, 240, 386-391.	1.7	6
30	XOR inhibition with febuxostat accelerates pulmonary endothelial barrier recovery and improves survival in lipopolysaccharide-induced murine sepsis. <i>Physiological Reports</i> , 2017, 5, e13377.	1.7	9
31	Evaluation of criteria for exercise-induced pulmonary hypertension in patients with resting pulmonary hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1700784.	6.7	7
32	Right ventricular longitudinal strain is diminished in systemic sclerosis compared with idiopathic pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2017, 50, 1701436.	6.7	37
33	Use of thermodilution cardiac output overestimates diagnoses of exercise-induced pulmonary hypertension. <i>Pulmonary Circulation</i> , 2017, 7, 253-255.	1.7	17
34	Abstract 21027: Prognostic Evaluation and Risk Assessment in Scleroderma Patients With Newly Diagnosed Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 136, .	1.6	1
35	Heart Rate Dependence of the Pulmonary Resistance x Compliance (RC) Time and Impact on Right Ventricular Load. <i>PLoS ONE</i> , 2016, 11, e0166463.	2.5	32
36	Right Ventricular Functional Reserve in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2016, 133, 2413-2422.	1.6	149

#	ARTICLE	IF	CITATIONS
37	The Minimal Important Difference in Borg Dyspnea Score in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, 842-849.	3.2	30
38	Macrophage Migration Inhibitory Factor: A Novel Inhibitor of Apoptosis Signal-Regulating Kinase 1 α -p38 β -Xanthine Oxidoreductase β -Dependent Cigarette Smoke β -Induced Apoptosis. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016, 54, 504-514.	2.9	17
39	Health-related Quality of Life and Survival in Pulmonary Arterial Hypertension. <i>Annals of the American Thoracic Society</i> , 2016, 13, 31-39.	3.2	65
40	Bidimensional Measurements of Right Ventricular Function for Prediction of Survival in Patients with Pulmonary Hypertension: Comparison of Reproducibility and Time of Analysis with Volumetric Cardiac Magnetic Resonance Imaging Analysis. <i>Pulmonary Circulation</i> , 2015, 5, 527-537.	1.7	13
41	Right Ventricular Angiogenesis is an Early Adaptive Response to Chronic Hypoxia β -Induced Pulmonary Hypertension. <i>Microcirculation</i> , 2015, 22, 724-736.	1.8	28
42	Cyclin-Dependent Kinase Five Mediates Activation of Lung Xanthine Oxidoreductase in Response to Hypoxia. <i>PLoS ONE</i> , 2015, 10, e0124189.	2.5	8
43	Right Ventricular Remodeling in Idiopathic and Scleroderma β -Associated Pulmonary Arterial Hypertension: Two Distinct Phenotypes. <i>Pulmonary Circulation</i> , 2015, 5, 327-334.	1.7	22
44	Ambrisentan and Tadalafil Up-front Combination Therapy in Scleroderma-associated Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 1102-1110.	5.6	138
45	MK2 Phosphorylates Capase 3 and Regulates Nuclear Translocation of Cleaved Caspase 3 during LPS mediated Apoptosis. <i>FASEB Journal</i> , 2015, 29, 661.8.	0.5	0
46	Abstract 14254: Right Ventricular Reverse Remodeling and Improved Systolic Function After Upfront Combination Therapy With Ambrisentan and Tadalafil in the Treatment of Scleroderma-Associated Pulmonary Arterial Hypertension. <i>Circulation</i> , 2015, 132, .	1.6	0
47	Abstract 17885: Pulmonary Vascular Compliance Predicts Mortality in the Acute Respiratory Distress Syndrome. <i>Circulation</i> , 2015, 132, .	1.6	0
48	Mitogen-Activated Protein Kinase β -Activated Protein Kinase 2 Mediates Apoptosis during Lung Vascular Permeability by Regulating Movement of Cleaved Caspase 3. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2014, 50, 932-941.	2.9	39
49	Prognostic value of the pre-transplant diastolic pulmonary artery pressure β to β pulmonary capillary wedge pressure gradient in cardiac transplant recipients with pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 289-297.	0.6	123
50	A 32-Year-Old Woman With Dyspnea, Lung Cysts, and Previous Pneumothoraces. <i>Chest</i> , 2013, 144, 1964-1968.	0.8	2
51	Right Ventricular Dysfunction in Chronic Lung Disease. <i>Cardiology Clinics</i> , 2012, 30, 243-256.	2.2	46
52	Linking new and old concepts: inflammation meets the Warburg phenomenon in pulmonary arterial hypertension. <i>Journal of Molecular Medicine</i> , 2011, 89, 729-732.	3.9	3